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Abstract
Background: HDL function rather than absolute level may be a more accurate indicator for risk of developing
atherosclerosis. Dysfunctional HDL has increased redox activity and reduced antioxidant properties, but it is
unknown whether abnormal HDL function is associated with progression of atherosclerosis in HIV-1-infected
subjects.
Findings: We retrospectively measured serum HDL function in 91 subjects from a prospective 3-year study of
carotid artery intima-media thickness (CIMT), which enrolled triads of risk factor-matched persons that were
HIV-1-uninfected (n=36) or HIV-1+ with (n=29) or without (n=26) protease inhibitor (PI)-based therapy for ≥ 2 years.
HDL function was assessed using a biochemical assay that measures the oxidation of dihydrorhodamine 123
(DHR oxidation rate, DOR), in which higher DOR readout corresponds to dysfunctional HDL phenotype.
There were no significant associations between DOR and HIV-1 infection. In univariate analysis of 55 HIV-1-infected
subjects, greater waist circumference and lower serum HDL were significantly associated with higher baseline levels
of DOR (p=0.01). These subjects had significant increases in levels of DOR over time (3 years) that were associated
with white race (p=0.03), higher nadir CD4 count (p<0.001), and lower baseline CIMT (p<0.001). Lower baseline HDL
levels, but not function of HDL (p>0.1) (DOR), were significantly associated (p=0.02) with progression of CIMT.
Conclusion: In a small matched cohort study of HIV-1-infected subjects who had a low cardiovascular risk profile,
HDL function changed over time and was independently associated with anthropometric parameters of obesity but
not with progression of CIMT.
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Findings
Introduction
High-density lipoprotein (HDL) function rather than
absolute level may be a more accurate indicator for risk
of developing atherosclerosis [1]. Systemic inflammation
may involve the conversion of HDL to a dysfunctional
form that is no longer cardioprotective and contributes
to the risk of coronary disease [2,3]. Dysfunctional HDL
has increased redox activity [4] and reduced antioxidant
properties that may contribute to atherogenesis [5,6].
We have recently shown that HIV-1-infected (HIV-1+)
subjects have dysfunctional HDL [4,7,8]. However, no
study has directly explored the relationships between
dysfunctional HDL, HIV-1 infection and progression of
atherosclerosis as well as predictors of dysfunctional
HDL in HIV-1 infection.
Using a recently developed biochemical assay that quan-
tifies the redox activity of HDL based on the oxidation
rate of the fluorogenic probe dihydrorhodamine 123
(DOR) [4] and serum specimens from a previously
reported clinical study, we examined the longitudinal
association of DOR with the progression of atheroscler-
osis, as evaluated by measurement of carotid artery intima-
media thickness (CIMT), in HIV-1-infected (HIV-1+)
and -uninfected (controls) individuals. Since residual
immune activation despite antiretroviral treatment may
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HIV-1+ persons [8] and progression of atherosclerosis
[9], we also investigated possible associations between
DOR and biomarkers of macrophage activation, such as
soluble CD14 (sCD14) and biomarkers of bacterial
translocation such as lipopolysaccharide (LPS) [10].
Methods
The current study is a subset analysis of samples obtained
from a prospective, matched cohort study [9] in which sub-
jects were enrolled as risk factor-matched triads of HIV-1+
individuals with viremia < 500 RNA copies/ml with (n=29)
or without (n=26) use of PI therapy, and HIV-1-uninfected
(control) individuals (n=36) from 41 triads.
Presence of metabolic syndrome, CIMT and baseline
variables (fasting glucose, lipids, insulin, cardiovascular
disease-related measurements, CD4
+ Tc e l lc o u n t sa n d
HIV RNA levels, high-sensitivity C-reactive protein, serum
sCD14, serum LPS) have previously been determined [9].
Stored samples from baseline and week 144 (or 96 if week
144 was missing) were assayed. HDL was isolated using
ultracentrifugation and the DOR of each sample was de-
termined as previously [4] and was normalized (nDOR) as
ratio to the DOR of a control HDL isolated from pooled
serum from healthy subjects (see Additional file 1).
Matched analyses comparing the combined HIV-1+
group to the controls (N=32) assessed the effect of HIV-1
infection on nDOR. Progression of atherosclerosis was
evaluated as yearly rate of change in CIMT (ΔCIMT); and
CIMT progression (previously defined as yearly rate of
change ≥ 12.2 μm/yr) [9]. Mixed models regression with
triad as a random effect and repeated measures regression
evaluated associations of baseline measurements of nDOR
and yearly rates of change in the outcome, respectively,
with baseline covariates. SAS 9.2 (SAS Institute Inc., Cary,
NC, USA) was used for all statistical analyses.
Results
HIV-1+ subjects had more metabolic abnormalities than
the control subjects
As reported previously the HIV-1+ subjects in this
cohort had significantly (p<0.05) higher presence of
metabolic syndrome, higher levels of total cholesterol,
triglycerides and non-HDL cholesterol and insulin levels,
serum sCD14 and similar levels of serum LPS compared
to the control subjects [9]. Due to matching the groups
were similar with respect to age, sex, race, body mass
index (BMI), LDL and HDL levels [9].
HIV-1 infection was not significantly associated with
baseline HDL function, but HDL function changed
significantly over time within the HIV-1+ subjects
In view of our previous findings that HIV-1+ subjects
have dysfunctional HDL [4,7,8], we investigated possible
associations between treated HIV-1 infection and changes
in serum nDOR. As shown in Table 1, at baseline and
week 96/144, serum nDOR were not significantly different
between both HIV-1+ groups (with and without PI treat-
ment) and in the combined HIV-1+ group compared to
the controls (p>0.2). Although the HIV/non-PI group had
a significant increase in relative median levels of nDOR of
0.17 (p=0.01) by 96/144 weeks compared to baseline, there
was a trend towards significant increases in nDOR over
time (yearly rate of change in nDOR or ΔnDOR) within
the combined HIV-1+ group (p=0.08); this was not seen
within the HIV/PI and not HIVgroups (p>0.3).
Lower baseline HDL levels and anthropometric
parameters of obesity were independently associated
with HDL function
It is unknown which parameters may independently predict
changes in HDL function in HIV-1+ subjects. In univariate
analysis of HIV-1+ subjects, HDL cholesterol <35 mg/dl
(p=0.007), increased baseline waist-to-hip ratio (WHR;
p=0.02), and higher baseline BMI (p=0.086) were asso-
ciated with higher baseline nDOR (Table 2). In the con-
trol subjects, HDL cholesterol <35 mg/dl (p=0.03),
baseline waist circumference ≥90 cm (p=0.097), and
increased baseline WHR (p=0.071) were univariately
associated with higher baseline nDOR. These data con-
firm previous findings in HIV-1-uninfected subjects
that obesity and lower HDL levels are associated with
dysfunctional HDL [11].
Changes in HDL function over time were associated with
baseline HDL, race, nadir CD4 count, and CIMT in HIV-1+
subjects
Because there were significant changes in nDOR over
time within the HIV-1+ group, we sought factors that
were associated with yearly rate of change in HDL function
(ΔnDOR) in HIV-1+ subjects. Similar to the univariate
analysis (Table 2), multivariate analysis in HIV-1+ sub-
jects showed a positive ΔnDOR was associated with
lower baseline CIMT (parameter estimate 0.45, 95% CI:
0.23-0.67; p<0.001), white race (estimate 0.12, 95% CI:
0.01-0.23; p=0.03), baseline HDL ≥35 mg/dl (estimate
0.07, 95% CI: 0.02-0.12; p=0.007), and nadir CD4 >200
cells/mm
3 (estimate 0.08, 95% CI: 0.04-0.12; p<0.001).
In the control subjects, lower baseline LPS (p=0.03)
and decreased baseline insulin (p=0.002) were associ-
ated with a positive ΔnDOR in multivariate analysis.
There were too few non-white subjects to determine
the effect of race on ΔnDOR. Finally, increased rate of
change in nDOR in HIV-1+ subjects was associated
with favorable metabolic and immunologic parameters
with higher baseline HDL levels, in contrast to baseline
nDOR, which was associated with lower HDL levels.
Further larger prospective studies will be required to
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http://www.lipidworld.com/content/12/1/23Table 1 Summary of normalized to control (pooled HDL sample from all study subjects) DOR (nDOR) results [Median (IQR)] by group and of parameters that
were significantly associated with nDOR and normalized Yearly Rate of Change in nDOR (ΔnDOR) (see Table 2)
Characteristic Total (N=91) HIV (N=55) HIV/PI (N=29) HIV/non-PI (N=26) Not HIV (N=36) P value
Baseline nDOR 1.64 (1.47, 2.02) 1.62 (1.44, 1.96) 1.60 (1.46, 1.95) 1.65 (1.44, 1.96) 1.65 (1.51, 2.07) 0.41
1; 0.70
2
Week 96/144 nDOR 1.80 (1.50, 2.00) 1.80 (1.45, 1.92) 1.79 (1.45, 1.83) 1.82 (1.45, 2.29) 1.82 (1.53, 2.14) 0.36
1;0.27
2
Yearly rate of change in nDOR 0.009 (-0.055, 0.108) 0.005 (-0.048, 0.110) -0.004 (-0.055, 0.101) 0.059 (-0.031, 0.118) 0.009 (-0.059, 0.102) 0.94; 0.58; 0.29; 0.65
3
P Value for ΔnDOR within group
4 - 0.08 0.92 0.01 0.31 -
Sex (Male) 84 (92%) 52 (95%) 28 (97%) 24 (92%) 32 (89%) 0.43
1; 0.55
5
White non-Hispanic race 69 (76%) 42 (76%) 23 (79%) 19 (73%) 27 (75%) 0.62
1; 0.40
5
Body mass index (kg/m
2) 24.70 (23.40-27.60) 24.60 (23.20-27.40) 25.50 (23.60-27.60) 24.20 (22.00-26.60) 25.00 (23.75-27.95) 0.55
1; 0.25
2
Waist circumference (cm) ≥ 90
6 40 (44%) 24 (44%) 17 (59%) 7 (27%) 16 (44%) 1.0
1; 0.05
5
Waist/Hip ratio
6 0.91 (0.86-0.94) 0.92 (0.88-0.95) 0.93 (0.92-0.96) 0.90 (0.86-0.94) 0.89 (0.83-0.92) 0.006
1; 0.003
2
Baseline CIMT (μm) 707.5 (640.0-767.0) 715.0 (640.0-771.0) 752.0 (631.0-778.5) 701.3 (669.5-760.5) 684.0 (639.5-758.0) 0.48
1, 0.56
2
Nadir CD4+ T-cells ≤ 200 (cells/mm
3)
7 (-) 20 (36%) 11 (39%) 9 (35%) (-) 0.78
5
HDL Cholesterol < 35 (mg/dl) 20 (22%) 13 (24%) 7 (24%) 6 (23%) 7 (19%) 0.64
1; 0.90
5
Insulin mU/l
8 6.25 (5-8) 6.50 (5.10-10.70) 7.40 (6.20-14.50) 5.55 (4.55-7.15) 6 (5-7.60) 0.16
1; 0.004
2
LPS (pg/ml) 453.2 (243.5-795.5) 439.4 (207.1-719.5) 453.2 (273.5-635.9) 352.5 (189.2-939.2) 496.6 (246.4-1040) 0.26
1; 0.52
2
Notes:
1 Wilcoxon test for between group differences: HIV versus not HIV.
2 Kruskal-Wallis test for between group differences: HIV/PI versus HIV/non-PI versus Not HIV.
3 Wilcoxon p-value for matched group differences within each visit week: pairings assessed were HIV versus not HIV (N=32 matched pairings), HIV/PI versus HIV/non-PI (N=18 matched pairings), HIV/PI versus not HIV
(N=26 matched pairings), and HIV/non-PI versus not HIV (N=21 matched pairings).
4 Wilcoxon test for non-zero yearly rate of change within each group.
5 Fisher’s Exact test for between group differences: HIV/PI versus HIV/non-PI versus Not HIV.
6 Due to missing data, the sample sizes are N=90, N=28, N=26, and N=36.
7 Due to missing data, the sample sizes are N=53, N=27, and N=26.
8 Due to missing data, the sample sizes are N=84, N=27, N=24, and N=33.
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3explore these findings and determine predictors of both
baseline HDL function and changes in HDL function
over time.
HDL function was not associated with progression of
subclinical atherosclerosis in HIV-1+ subjects
Considering the previously described role of HDL func-
tion in progression of atherosclerosis in HIV-1-uninfected
subjects, we investigated the possible relationship between
HDL function and progression of atherosclerosis in
HIV-1+ subjects. In a prior multivariate analysis in the
HIV-1+ subjects, baseline HDL <35 mg/dl (p=0.04) and
higher levels of baseline sCD14 (p=0.04) and LPS
(p=0.003) were associated with a positive ΔCIMT [9].
In univariate analysis in HIV-1+ subjects, baseline
nDOR was not associated with baseline CIMT (esti-
mate: 53.2; 95% CI: (-16.6-123; p=0.13), ΔCIMT (esti-
mate: -7.5; 95% CI: (-15.6- 0.7; p=0.07), and CIMT
progression (estimate: 0.8; 95% CI: 0.2-3.6; p=0.81). It is
possible that different factors influence the presence of
plaque and CIMT, and thus the relationship of HDL
function with different measures of atherosclerosis [9]
requires further examination in larger studies.
The interaction of the HDL redox activity with levels of
cholesterol may be important in HIV-1+ subjects
The redox activity of HDL may depend on the interplay
between HDL and LDL and the concentrations of both
H D La n dL D La n dt h e i rr a t i o( L D L / H D L )[ 3 , 4 ] .I nH I V - 1 +
subjects, the baseline interaction model of nDOR*
(LDL/HDL), including HDL, LDL/HDL, and nDOR*HDL,
nDOR*(LDL/HDL) was significantly associated with base-
line CIMT (estimate: 120; 95% CI: 15.4-225; p=0.03), but
not with CIMT progression (OR: 0.5; 95% CI: 0.06-4.5;
p=0.55), and ΔCIMT (estimate: -3.5; 95% CI: -14.2-7.3;
p=0.52). Thus, the interaction of the HDL redox activity
with levels of cholesterol may be taken into consideration
when studying the association of dysfunctional HDL with
atherosclerosis in HIV-1+ subjects who are known to have
dyslipidemia and dysfunctional HDL [4,7,12].
HDL redox activity was not associated with biomarkers of
macrophage activation in HIV-1+ subjects
Residual immune activation despite effective antiretro-
viral therapy could contribute to the presence of dys-
functional HDL in HIV-1 infection [8,13,14]. However,
despite the significantly higher baseline levels of sCD14,
a marker of macrophage activation, in HIV-1+ compared
to control subjects [10] in our small study, we did not
detect any significant associations between nDOR and
sCD14 (p>0.1). Larger studies are needed to elucidate
the role of dysfunctional HDL in HIV-1-induced
immune activation.
Limitations/conclusion
Our study had limited statistical power to detect small
differences in HDL redox activity between groups, espe-
cially in the context of the limitations of the DHR assay
(see Additional file 1). Moreover, despite preliminary
data from in vitro studies that support a role of oxi-
Table 2 Univariate associations of nDOR with baseline variables
HIV-1+ subjects Control subjects
Covariate Parameter estimate (95% CI) P value Parameter estimate (95% CI) P value
Baseline nDOR (normalized ratio)
HDL Cholesterol (ref: ≥35 mg/dl) 0.357 (0.114, 0.601) 0.007 0.365 (0.029, 0.701) 0.034
Body mass index (per 1 kg/m
2 increase) 0.032 (-0.005, 0.069) 0.086 (-) (-)
Waist circumference (ref: <90 cm) (-) (-) 0.231 (-0.044,0.506) 0.097
Waist/Hip ratio (per 0.1 unit increase) 0.212 (0.035, 0.388) 0.022 0.215 (-0.019, 0.448) 0.071
Yearly rate of change in nDOR (normalized ratio/yr).
Male sex 0.156 (-0.018, 0.329) 0.078 0.067 (-0.001, 0.144) 0.085
White vs Non-White 0.119 (0.033, 0.206) 0.008 (-) (-)
Body mass index (per 1 kg/m
2 increase) (-) (-) -0.010 (-0.020, 0.0001) 0.051
Reported Nadir CD4 (ref: <200 cells/mm
3) 0.083 (0.039, 0.128) <0.001 (-) (-)
Baseline CIMT (per 1 μm decrease) 0.474 (0.229, 0.719) <0.001 (-) (-)
HDL Cholesterol (ref: ≥35 mg/dl) -0.055 (-0.109, -0.001) 0.046 (-) (-)
Insulin (per 10 mU/l decrease) (-) (-) 0.120 (0.056, 0.184) <0.001
LPS (per 100 pg/ml decrease) (-) (-) 0.005 (0.002, 0.008) 0.005
The baseline variables considered for all subjects were age, gender, race, fasting lipid measurements [total cholesterol, low density lipoprotein (LDL) cholesterol,
HDL cholesterol, triglycerides, and non-HDL cholesterol], use of lipid lowering drugs, fasting glucose, body mass index, waist circumference, waist/hip ratio, insulin,
high-sensitivity C-reactive protein, homocysteine, sCD14, LPS, and CIMT. For the HIV-1-infected subjects, additional covariates included years of PI use, CD4+ T-cell
count, and nadir CD4+ T-cell count.
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nDOR, which is a biochemical and not a physiological
parameter, in studying atherosclerosis in vivo, needs to
be validated in large-scale human studies.
Despite these limitations, our study is among the first
attempts to measure HDL function in HIV-1+ and con-
trols longitudinally and define their possible associations
with progression of subclinical atherosclerosis. Thus, this
study may set the basis for further studies on the role of
HDL function in HIV-1 infection given that standard
clinical lipid profile testing may not be an adequate
measurement of the risk for atherosclerosis.
Additional file
Additional file 1: Supplemental material.
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